Henan Cancer Hospital

This early-phase trial tests whether injecting methotrexate-loaded vesicles (tiny drug-carrying particles made from patients' own tumor cells) into the spinal fluid can safely treat lung cancer that has spread to the brain lining. About 14 adults who have failed standard treatmen…

This study tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy can help shrink tumors or slow disease in people with advanced HER2-negative breast cancer. About 92 adults whose cancer has worsened after prior treatments will receive the combinat…

This study is testing a combination of two drugs, utidelone and bevacizumab, in people with advanced HER-2 negative breast cancer who have already tried at least two other treatments. The goal is to see if this combination can slow down the cancer's growth and improve outcomes. A…

This study tests an experimental drug called SHR-A1811 in people with advanced breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. The trial enrolls 150 adults with HER2-positive or HER2-low breast cancer who have not had radiation …

This study tests a combination of three drugs (fruquintinib, trastuzumab, and chemotherapy) as a first treatment for people with HER2-positive advanced stomach or gastroesophageal junction cancer. The goal is to see if the combo is safe and can shrink tumors or slow cancer growth…

This study tests whether adding the drug QL1706 to standard chemotherapy before surgery can eliminate more cancer in people with early HR+/HER2- breast cancer. About 238 participants will receive either the combination or chemo alone for 6 cycles, then have surgery. After surgery…

This early-phase trial is testing a new treatment called RE002 T cells for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The study will enroll 30 adults who have run out of standard options. Participants first receive chemotherapy to prep…

This study tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery can eliminate all cancer in patients with early triple-negative breast cancer. About 64 participants will receive this trea…

This study tests a new treatment called BioTTT001, a modified virus designed to attack cancer cells, in 42 adults with recurrent non-small cell lung cancer that has spread to the lining of the brain. The treatment is given through a small device placed in the head. The main goals…

This study looks at a two-drug combination (zanubrutinib and rituximab) as a first treatment for people with marginal zone lymphoma, a slow-growing blood cancer. About 30 participants will receive the combo to see how well it shrinks tumors and delays the cancer from getting wors…

This study tests a drug called efbemalenograstim alfa to prevent febrile neutropenia—a serious infection risk—in people with solid tumors undergoing chemotherapy. About 1,076 participants will receive the injection either as a first-time prevention or after a prior low white bloo…

This study looks at whether a technology that analyzes immune system T cells can predict how well a combination of the drug tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. Researchers will enroll 40 patients who have not yet be…